Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,010,848
  • Shares Outstanding, K 143,922
  • Annual Sales, $ 330,530 K
  • Annual Income, $ -145,220 K
  • EBIT $ -490 M
  • EBITDA $ -517 M
  • 60-Month Beta 1.35
  • Price/Sales 9.05
  • Price/Cash Flow N/A
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 79.92% ( +8.48%)
  • Historical Volatility 55.58%
  • IV Percentile 84%
  • IV Rank 55.67%
  • IV High 102.52% on 12/20/24
  • IV Low 51.56% on 07/16/24
  • Put/Call Vol Ratio 2.00
  • Today's Volume 3
  • Volume Avg (30-Day) 141
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 1,134
  • Open Int (30-Day) 3,489

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.87
  • Number of Estimates 12
  • High Estimate -0.73
  • Low Estimate -0.97
  • Prior Year -0.86
  • Growth Rate Est. (year over year) -1.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.49 +2.10%
on 12/24/24
26.18 -20.09%
on 12/09/24
-3.77 (-15.27%)
since 11/22/24
3-Month
20.49 +2.10%
on 12/24/24
33.33 -37.23%
on 11/11/24
-9.40 (-31.00%)
since 09/24/24
52-Week
14.56 +43.68%
on 04/25/24
33.33 -37.23%
on 11/11/24
-1.04 (-4.74%)
since 12/22/23

Most Recent Stories

More News
Denali Therapeutics Initiates Phase 2a Clinical Study of LRRK2 Inhibitor BIIB122 for Parkinson’s Disease

Denali Therapeutics initiates a Phase 2a study of BIIB122 for LRRK2-associated Parkinson's disease, evaluating safety and biomarkers.Quiver AI SummaryDenali Therapeutics Inc. has announced the start of...

DNLI : 20.92 (+0.67%)
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

DNLI : 20.92 (+0.67%)
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

DNLI : 20.92 (+0.67%)
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

TECH : 73.03 (+0.40%)
XLV : 139.32 (+0.41%)
DNLI : 20.92 (+0.67%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 20.92 (+0.67%)
FHTX : 5.02 (+1.83%)
MRNA : 40.27 (+1.72%)
OMGA : 0.8322 (+2.61%)
SANA : 1.7500 (+7.36%)
MCRB : 0.9600 (-0.53%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 20.92 (+0.67%)
FHTX : 5.02 (+1.83%)
MRNA : 40.27 (+1.72%)
OMGA : 0.8322 (+2.61%)
SANA : 1.7500 (+7.36%)
MCRB : 0.9600 (-0.53%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 20.92 (+0.67%)
FHTX : 5.02 (+1.83%)
MRNA : 40.27 (+1.72%)
OMGA : 0.8322 (+2.61%)
SANA : 1.7500 (+7.36%)
MCRB : 0.9600 (-0.53%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 20.92 (+0.67%)
FHTX : 5.02 (+1.83%)
MRNA : 40.27 (+1.72%)
OMGA : 0.8322 (+2.61%)
SANA : 1.7500 (+7.36%)
MCRB : 0.9600 (-0.53%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 20.92 (+0.67%)
FHTX : 5.02 (+1.83%)
MRNA : 40.27 (+1.72%)
OMGA : 0.8322 (+2.61%)
SANA : 1.7500 (+7.36%)
MCRB : 0.9600 (-0.53%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 20.92 (+0.67%)
FHTX : 5.02 (+1.83%)
MRNA : 40.27 (+1.72%)
OMGA : 0.8322 (+2.61%)
SANA : 1.7500 (+7.36%)
MCRB : 0.9600 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 21.74
2nd Resistance Point 21.41
1st Resistance Point 21.16
Last Price 20.92
1st Support Level 20.58
2nd Support Level 20.25
3rd Support Level 20.00

See More

52-Week High 33.33
Fibonacci 61.8% 26.16
Fibonacci 50% 23.95
Fibonacci 38.2% 21.73
Last Price 20.92
52-Week Low 14.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar